US 12286479
Treatment with anti-α4β7 antibody
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 12286479 (Treatment with anti-α4β7 antibody) held by Takeda Pharmaceutical Company Limited expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K39/39591